AtriCure (NASDAQ:ATRC) Price Target Raised to $70.00

AtriCure (NASDAQ:ATRC) had its price target raised by Needham & Company LLC from $64.00 to $70.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The brokerage presently has a “buy” rating on the medical device company’s stock. Needham & Company LLC‘s price objective suggests a potential upside of 15.87% from the stock’s previous close.

A number of other research analysts have also issued reports on ATRC. Stifel Nicolaus set a $65.00 target price on shares of AtriCure in a research note on Thursday, September 17th. Weiss Ratings upgraded shares of AtriCure from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, October 8th. Zacks Research lowered shares of AtriCure from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 24th. Raymond James Financial set a $52.00 price target on shares of AtriCure in a report on Tuesday, July 21st. Finally, Citigroup reaffirmed a “market outperform” rating on shares of AtriCure in a research report on Wednesday, October 21st. Six equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $57.00.

AtriCure Trading Up 0.9%

Shares of ATRC stock opened at $60.41 on Wednesday. AtriCure has a 12 month low of $25.36 and a 12 month high of $63.00. The company has a quick ratio of 3.19, a current ratio of 4.22 and a debt-to-equity ratio of 0.14. The business’s 50 day moving average is $56.03 and its two-hundred day moving average is $38.40. The company has a market cap of $3.07 billion, a PE ratio of 260.35 and a beta of 1.23.

AtriCure (NASDAQ:ATRC) last released its quarterly earnings results on Tuesday, November 3rd. The medical device company reported $0.17 EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.23. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. The company had revenue of $154.45 million for the quarter, compared to analyst estimates of $151.05 million. Equities analysts predict that AtriCure will post 0.29 EPS for the current year.

Insider Transactions at AtriCure

In other news, insider Karl Dahlquist sold 9,370 shares of the company’s stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $48.89, for a total transaction of $458,099.30. Following the completion of the transaction, the insider directly owned 87,319 shares in the company, valued at $4,269,025.91. The trade was a 9.69% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Regina Groves sold 5,313 shares of the stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $54.22, for a total value of $288,070.86. Following the completion of the sale, the director directly owned 34,546 shares of the company’s stock, valued at $1,873,084.12. This represents a 13.33% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 30,622 shares of company stock worth $1,626,003 over the last three months. 4.00% of the stock is currently owned by insiders.

Hedge Funds Weigh In On AtriCure

Large investors have recently bought and sold shares of the stock. BlackRock Inc. bought a new stake in AtriCure in the 2nd quarter valued at $125,198,000. Wellington Management Group LLP grew its position in AtriCure by 3.3% in the 2nd quarter. Wellington Management Group LLP now owns 3,495,603 shares of the medical device company’s stock worth $97,807,000 after purchasing an additional 113,048 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of AtriCure by 8.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 997,759 shares of the medical device company’s stock worth $28,466,000 after purchasing an additional 75,862 shares during the period. Bank of America Corp DE bought a new position in shares of AtriCure during the 2nd quarter worth about $24,465,000. Finally, Grandeur Peak Global Advisors LLC acquired a new position in shares of AtriCure during the second quarter valued at about $16,435,000. 99.11% of the stock is currently owned by institutional investors and hedge funds.

More AtriCure News

Here are the key news stories impacting AtriCure this week:

• Positive Sentiment: AtriCure reported third-quarter EPS of $0.17 and revenue of $154.45 million, beating analyst estimates of $151.05 million in revenue. The better-than-expected results prompted analysts to increase their forecasts. AtriCure beats Q3 estimates
• Positive Sentiment: BTIG raised its price target to $70, while broader analyst coverage also reported upward forecast revisions after the quarterly results. Such revisions signal improved expectations for the company. BTIG raises AtriCure price target
• Positive Sentiment: The company expects 2026 revenue of $606 million to $610 million and adjusted EBITDA of $91 million to $94 million, providing investors with its latest financial outlook. AtriCure 2026 outlook and enrollment update
• Neutral Sentiment: AtriCure is targeting completion of BoxX-NoAF enrollment by year-end. This is a clinical-program milestone, though the article listing provides no results or details on potential timing or impact. BoxX-NoAF enrollment update

About AtriCure

AtriCure, Inc is a medical device company that develops and sells products for the surgical treatment of atrial fibrillation (AFib) and related conditions. Its technologies are designed to support cardiac surgeons and electrophysiologists performing tissue ablation, left atrial appendage management and other procedures intended to restore or maintain normal heart rhythm.

The company’s product portfolio includes the AtriClip device, which is used to exclude the left atrial appendage, along with surgical ablation systems such as the Isolator Synergy clamps and cryoablation products.